The first sale of Hemgenix (etranacogene dezaparvovec) has triggered a $100 million milestone payment for the gene therapy’s original developer, uniQure 20 June 2023
Danish allergy company ALK has announced Carsten Hellman will step down as chief executive, to be replaced by current Fertin Pharma CEO Peter Halling. 19 June 2023
Biogen has announced several changes to its board of directors, with Alexander Denner, William Jones and Richard Mulligan opting not to stand for re-election. 15 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.